A Study of Belzutifan Plus Pembrolizumab Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post-Nephrectomy
The purpose of this study is to assess the efficacy and safety of oral belzutifan (MK-6482) plus intravenous (IV) pembrolizumab (MK-3475) compared to placebo plus pembrolizumab, in the adjuvant treatment of Clear Cell Renal Cell Carcinoma (ccRCC) post-nephrectomy. The primary study hypothesis is that belzutifan plus pembrolizumab is superior to placebo plus pembrolizumab with respect … Continued